Physician-Reported Patient Share for Regeneron’s Eylea Has Now Stabilized Following Significant Increases after Its U.S. Launch for Wet Age-Related Macular Degeneration

August 14, 2014

Over Three-Quarters of Physicians View Ophthotech’s Fovista as an Emerging Therapy with High Potential Value for Wet AMD, According to Findings from Decision Resources Group

BURLINGTON, Mass., Aug. 14, 2014 /PRNewswire/ — Decision Resources Group finds that physician-reported patient shares for Regeneron’s Eylea, as well as the other major anti-vascular endothelial growth factor (VEGF) agents Genentech/Roche’s Avastin and Genentech/Roche’s Lucentis, have now stabilized among wet age-related macular degeneration (AMD) patients, following significant movement after the 2011 U.S. launch of Eylea. Although off-label compounded Avastin, with its low cost, continues to be the U.S. patient share leader and most-preferred option for wet AMD, Eylea slightly edges out Lucentis as the preferred second-line treatment approach–driven by physicians’ positive perceptions of Eylea’s efficacy and its convenient dosing frequency.


Other key findings from the TreatmentTrends: Dry/Wet AMD 2014 (US) report:

    --  Dosing schedules for anti-VEGF agents: U.S. physicians reported that at
        least one-quarter of wet AMD patients treated with Avastin, Eylea or
        Lucentis are administered these agents using a treat and extend (TAE)
        approach, suggesting that physicians use individualized treatment
        approaches for at least some of their patients. In fact, a larger
        percentage of physicians agreed that using a TAE protocol, rather than
        the approved dosing or a PRN (i.e. as needed) schedule, produces the
        best long-term outcomes for wet AMD.
    --  Emerging therapies for wet AMD: More than three-quarters of surveyed
        physicians selected Ophthotech's Fovista as one of two products that
        would bring the most value to the treatment of wet AMD, a significantly
        larger percentage than those who chose the other emerging wet AMD
        products profiled--Allergan's abicipar pegol (anti-VEGF DARPin), Lpath's
        iSONEP and Ohr Pharmaceutical's Squalamine. The perceived value of
        adjunctive Fovista is largely driven by its novel mechanism of action as
        an anti-platelet derived growth factor (PDGF) agent and its anticipated
        efficacy based upon available Phase IIb clinical data.

Comments from Decision Resources Group Analyst Emma McFadden, Ph.D.:

    --  "Considering the paucity of approved therapies for dry AMD, it is not
        surprising that most surveyed physicians expressed at least moderate
        interest in learning more about the emerging dry AMD
        agents--Genentech/Roche's lampalizumab and Acucela/Otsuka's emixustat
        hydrochloride. However, lampalizumab was generally perceived to be the
        product that could offer the most value to the treatment of dry AMD, due
        largely to its novel mechanism of action and promising data thus far."
    --  "Given that anti-VEGF/anti-PDGF polypharmacy approaches are currently an
        area of active development, it is interesting to note that surveyed
        physicians show a preference for a coformulation of an anti-VEGF agent
        and anti-PDGF agent administered in one injection rather than an
        anti-PDGF agent administered adjunctively with any anti-VEGF agent in
        two separate injections at the same visit. Although this suggests that
        physicians may be reluctant to prescribe the adjunctive anti-PDGF
        therapy Fovista, this agent will likely launch many years before

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group

Christopher Comfort



Logo – http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

Source: PR Newswire

comments powered by Disqus